CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
COVID-19 in hematology patients: real world experience in hospitals in the UK West Midlands
Authors
Patrick Ball
Supratik Basu
+18 more
M.I. Hossain
Farheen Karim
Jahanzeb Khawaja
Bhuvan Kishore
Anandadeep Mandal
Hana Morrissey
Duncan Murray
Vidhya Murthy
Jeff Neilson
Alan M. Nevill
Manos Nikolousis
Shankara Paneesha
Nick Pemberton
N. Phillips
Guy Pratt
Katie Randall
J. Tanswell
Farooq Wandroo
Publication date
31 May 2021
Publisher
'Hilaris SRL'
Abstract
© 2021 The Authors. Published by Hilaris. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: [DOI/weblink]Objectives: This study aimed to understand the consequences of coronavirus disease 2019 (COVID-19) in patients diagnosed with haematological conditions, malignant and non-malignant. Method: A detailed insight into the first 112 patients with comorbidity of haematological conditions and COVID-19, admitted into nine National Health Services Trusts in the West Midlands Area of the United Kingdom, between 1st of March 2020 and 31st May 2020. Results: In the study cohort, 82% of patients had a malignant haematological disorder whilst 18% had a non-malignant haematological condition. Increasing age, breathlessness, reduction in oxygen saturation under 90% and abnormal chest x-ray were independently associated with higher mortality. Other long term co-morbidities did not present adverse impacts in this population. Survival analysis demonstrated that the COVID-19 severity score had a significant adverse correlation on patient outcome. COVID-19 patients who were classified as low risk, based on their primary haematological condition, showed significantly shorter survival time than those in the high risk category, which might be due to the shielding strategy for high infection risk patients. Conclusion: The 55% overall mortality in this cohort suggests that patients with haematological conditions had a higher mortality rate than patients with other acute, chronic or long term conditions. Significance: Previous studies have suggested poor outcomes for COVID‐19 infection in patients with haematological cancers, with short‐term mortality rates ranging from 32% to 62%. We report here the outcome of COVID-19 infection in patients with haematological conditions with both malignant and non-malignant, admitted to secondary care in acute care hospitals of the UK West Midlands. This study also examined the impact of chemo immunotherapy on outcomes from COVID-19 infection. This will be useful information to guide decision making during this second UK national lockdow
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
University of Birmingham Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:publications...
Last time updated on 04/01/2022
Wolverhampton Intellectual Repository and E-theses
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:wlv.openrepository.com:243...
Last time updated on 11/06/2021
University of Birmingham Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:openaire_cri...
Last time updated on 14/12/2021